Evidence map›Paper›PMID 27159557›Full record

ArticleBiotechnology and bioengineering2016

Mold-casted non-degradable, islet macro-encapsulating hydrogel devices for restoration of normoglycemia in diabetic mice.

Peter Daniel Rios, Xiaomin Zhang, Xunrong Luo, Lonnie D Shea

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. It's All in the Delivery: Designing Hydrogels for Cell and Non-viral Gene Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Review
  3. Article
  4. Polymeric Scaffolds for Pancreatic Tissue Engineering: A Review.The review of diabetic studies : RDS · 2018
    Review
  5. Spatially and Temporally Controlled Hydrogels for Tissue Engineering.Materials science & engineering. R, Reports : a review journal · 2017
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter Daniel RiosSimpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, 303 East Superior Street, Chicago, Illinois, 60611.
Xiaomin ZhangDivision of Transplantation, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Xunrong LuoDivision of Nephrology and Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Lonnie D SheaSimpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, 303 East Superior Street, Chicago, Illinois, 60611. ldshea@umich.edu.

Funding

Protein-Releasing Microporous Scaffolds for Cell Replacement TherapyR01EB009910 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUO, XUNRONG, SHEA, LONNIE D · 2010 to 2018
$3.5M
NIBIB NIH HHS R01 EB009910
6 · The paper itself

Abstract

Islet transplantation is a potential cure for diabetic patients, however this procedure is not widely adopted due to the high rate of graft failure. Islet encapsulation within hydrogels is employed to provide a three-dimensional microenvironment conducive to survival of transplanted islets to extend graft function. Herein, we present a novel macroencapsulation device, composed of PEG hydrogel, that combines encapsulation with lithography techniques to generate polydimethylsiloxane (PDMS) molds. PEG solutions are mixed with islets, which are then cast into PDMS molds for subsequent crosslinking. The molds can also be employed to provide complex architectures, such as microchannels that may allow vascular ingrowth through pre-defined regions of the hydrogel. PDMS molds allowed for the formation of stable gels with encapsulation of islets, and in complex architectures. Hydrogel devices with a thickness of 600 μm containing 500 islets promoted normoglycemia within 12 days following transplantation into the epididymal fat pad, which was sustained over the two-month period of study until removal of the device. The inclusion of microchannels, which had a similar minimum distance between islets and the hydrogel surface, similarly promoted normoglycemia. A glucose challenge test indicated hydrogel devices achieved normoglycemia 90 min post-dextrose injections, similar to control mice with native pancreata. Histochemical staining revealed that transplanted islets, identified as insulin positive, were viable and isolated from host tissue at 8 weeks post-transplantation, yet devices with microchannels had tissue and vascular ingrowth within the channels. Taken together, these results demonstrate a system for creating non-degradable hydrogels with complex geometries for encapsulating islets capable of restoring normoglycemia, which may expand islet transplantation as a treatment option for diabetic patients. Biotechnol. Bioeng. 2016;113: 2485-2495. © 2016 Wiley Periodicals, Inc.

Indexed as

Absorbable ImplantsAnimalsCapsulesCells, CulturedCell SurvivalDiabetes MellitusEquipment DesignEquipment Failure AnalysisHydrogelsIslets of LangerhansIslets of Langerhans TransplantationMaleMiceMice, Inbred C57BLTreatment OutcomeCapsulesHydrogelsencapsulationhydrogelmacroencapsulation devicemicrochannelspolydimethylsiloxane (PDMS)polyethylene glycol (PEG)

Identifiers

PMID27159557
PMCPMC11287382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.